These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 35092997

  • 1. [Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].
    Jiang L, Xiao K, Long H.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan 06; 56(1):87-94. PubMed ID: 35092997
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
    Bianchini D, Jayanth A, Chua YJ, Cunningham D.
    Clin Colorectal Cancer; 2008 Jan 06; 7(1):33-43. PubMed ID: 18279575
    [Abstract] [Full Text] [Related]

  • 3. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B.
    Acta Dermatovenerol Croat; 2016 Apr 06; 24(1):70-2. PubMed ID: 27149134
    [Abstract] [Full Text] [Related]

  • 4. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
    Barton-Burke M, Ciccolini K, Mekas M, Burke S.
    Nurs Clin North Am; 2017 Mar 06; 52(1):83-113. PubMed ID: 28189168
    [Abstract] [Full Text] [Related]

  • 5. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I, David M, Stemmer SM.
    Oncologist; 2010 Mar 06; 15(9):1002-8. PubMed ID: 20709888
    [Abstract] [Full Text] [Related]

  • 6. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A, Gutiérrez-Rivera A, López-Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, Arregui MA, Sarasqueta C, Lobo C, Tuneu A.
    Actas Dermosifiliogr; 2015 Mar 06; 106(6):483-92. PubMed ID: 25798804
    [Abstract] [Full Text] [Related]

  • 7. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA, Balagula Y, Lacouture ME, Anadkat MJ.
    Curr Opin Oncol; 2011 Jul 06; 23(4):343-51. PubMed ID: 21537180
    [Abstract] [Full Text] [Related]

  • 8. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
    Paul T, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Stingl JC.
    Eur J Cancer; 2014 Jul 06; 50(11):1855-63. PubMed ID: 24857781
    [Abstract] [Full Text] [Related]

  • 9. Clinical research of EGFR inhibitors and related dermatologic toxicities.
    Perez-Soler R, Van Cutsem E.
    Oncology (Williston Park); 2007 Oct 06; 21(11 Suppl 5):10-6. PubMed ID: 18154213
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B, Ayanoglu BT, Demirdag HG.
    Cutan Ocul Toxicol; 2019 Sep 06; 38(3):261-266. PubMed ID: 31010330
    [Abstract] [Full Text] [Related]

  • 12. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors.
    Lisi P, Bellini V, Bianchi L.
    Oncology; 2014 Sep 06; 87(5):311-9. PubMed ID: 25196815
    [Abstract] [Full Text] [Related]

  • 13. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T, Perez-Soler R.
    Target Oncol; 2009 Apr 06; 4(2):107-19. PubMed ID: 19452131
    [Abstract] [Full Text] [Related]

  • 14. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
    Ehmann LM, Heinemann V, Wollenberg A.
    Internist (Berl); 2011 Nov 06; 52(11):1359-64. PubMed ID: 21796420
    [Abstract] [Full Text] [Related]

  • 15. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J, Cencelj S.
    J Eur Acad Dermatol Venereol; 2010 Apr 06; 24(4):453-9. PubMed ID: 19793151
    [Abstract] [Full Text] [Related]

  • 16. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
    Wong SF, Lindgren A, Mummaneni M, Byun T, Vasko C, Arenos R, Alexson E, Osann K.
    J Support Oncol; 2010 Apr 06; 8(5):202-8. PubMed ID: 21086877
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.